Bristol-Myers Squibb Company Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Amylin Pharmaceuticals, Inc.

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) (“Bristol-Myers Squibb”) announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended (HSR), for its tender offer for Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) (“Amylin”) has expired.

Back to news